Gilead shakes hands with generics to make the most of tough Indian IP market
US biotechnology company Gilead Sciences has announced licence deals with Indian drugmakers that will see generic versions of one of its headline products sold at lower prices in emerging markets. The arrangement between Gilead and the generic…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.